Tarek Elrafei, DO
Hematology & Oncology · Bronx, NYNPI 1467563296
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $553 of the $743 with a category attached, or 74.5%. It is spread thinly across 14 manufacturers, the largest accounting for just 19.5%. Reporting peaked in 2020 at $174 and has fallen 52.5% since, to $83 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.
Across 55 payments — averaging $13.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aurobindo Pharma USA, Inc.$145
- Gilead$112
- AstraZeneca$109
- GE HealthCare$71
- Daiichi Sankyo Inc.$49
- Alnylam Pharmaceuticals Inc.$48
- plus $209 from 8 others
What the payments were for
- Food & beverage$55374%
- Education$19026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aurobindo Pharma USA, Inc. | 29 | $145 |
| Gilead(2 entities) | 5 | $112 |
| AstraZeneca | 5 | $109 |
| GE HealthCare | 1 | $71 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Alnylam Pharmaceuticals Inc. | 2 | $48 |
| Johnson & Johnson | 3 | $44 |
| Pfizer | 1 | $35 |
| Ipsen Biopharmaceuticals, Inc | 2 | $34 |
| Seagen Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Merck | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
How this compares
$743 in reported general payments places this provider in the 40th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 63 | $990,193 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 38 | $816,666 |
| PomalystPomalidomide | 37 | $765,951 |
| ImbruvicaIbrutinib | 26 | $578,612 |
| VenclextaVenetoclax | 30 | $460,576 |
| AranespDarbepoetin Alfa In Polysorbat | 166 | $404,607 |
| XtandiEnzalutamide | 23 | $388,023 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 72 | $378,865 |
| Lupron DepotLeuprolide Acetate | 54 | $313,067 |
| IbrancePalbociclib | 19 | $293,444 |
| CabometyxCabozantinib S-Malate | 11 | $286,385 |
| DopteletAvatrombopag Maleate | 18 | $281,983 |
| NubeqaDarolutamide | 20 | $277,602 |
| Neulasta OnproPegfilgrastim | 38 | $227,006 |
| VerzenioAbemaciclib | 13 | $198,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $17 | $937,14349 claims |
| PfizerOctagam, Ibrance, Eliquis | $35 | $730,419155 claims |
| Johnson & JohnsonProcrit, Xarelto | $44 | $182,016135 claims |
| MerckKeytruda | $18 | $121,86711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in Bronx
- Tauseef AhmedBronx$171K
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Francis ArenaLake Success$1M
- Sanjeev JainEast Patchogue$971K
- Ross LevineNew York$968K
- Perry CookBrooklyn$803K
- Mihir RavalAlbany$767K
- Joshua SabariNew York$761K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.